Lentiviral vector shortage looms unless manufacturing hurdles from clinical to commercial are addressed

With the an­tic­i­pa­tion that more gene ther­a­pies will en­ter the mar­ket, man­u­fac­tur­ers could strug­gle to meet de­mand if lentivi­ral vec­tor short­age risk is not tack­led, man­u­fac­tur­ing in­sid­ers told End­points News.

“The ma­jor­i­ty of the in­dus­try has fo­cused on a process [for lentivirus­es] that is not scal­able,” said Su­par­na Sanyal, Lon­za’s head of vi­ral vec­tor, com­mer­cial de­vel­op­ment, in an in­ter­view. “So there, the short­age is much more promi­nent,” she added.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.